Paul Harmatz - Concepedia

Author

Paul Harmatz

Also Known As

Aldrovandi, Grace, Bratkovic, Drago, Elliott P Vichinsky, Giugliani, Roberto, H Paul, H. Holle, H. Paul, HARINDER PAUL, Harmatz P, Harmatz Paul

553

Publications

14.6K

Citations

H-Index

220

Concepts

All Affiliations

UCSF Benioff Children's Hospital BioMarin (United States)Universidade Federal do Rio Grande do Sul Lurie Children's Hospital Johannes Gutenberg University Mainz

About

Paul Harmatz is an author at UCSF Benioff Children's Hospital specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	68	5.1K
2	Health Sciences	12	12	493
3	Education	2	2	28
4	Engineering	2	2	57
5	Natural Sciences	1	1	35

Paul Harmatz

166

Publications

10.4K

Citations

H-Index

Page 1

	Year	Citations
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Joseph Muenzer, J. E. Wraith, Michael Beck, Genetics in Medicine AllergyEnzyme Replacement TherapyInherited Metabolic DiseasePathogenesisMucopolysaccharidosis Ii	2006	578
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, The Journal of Pediatrics Translational MedicinePhase 3Enzyme Replacement TherapyImmunologyPathology	2006	361
Oxidative stress and inflammation in iron‐overloaded patients with <i>β</i>‐thalassaemia or sickle cell disease Patrick B. Walter, Ellen B. Fung, David W. Killilea, British Journal of Haematology Blood Transfusion TherapyIron MetabolismImmunologyIron DeficiencyRedox Biology	2006	282
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) Paul Harmatz, Chester B. Whitley, Lewis Waber, The Journal of Pediatrics Rare DiseasesEnzyme Replacement TherapyGenetic DisorderPathogenesisPathology	2004	273
Successful Treatment of Primary Amebic Meningoencephalitis James S. Seidel, Paul Harmatz, G. S. Visvesvara, New England Journal of Medicine Parasitic DiseasePrimary Amebic MeningoencephalitisPathogenesisGenera NaegleriaClinical Neurology	1982	237
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Joseph Muenzer, Michael Beck, Christine M. Eng, Genetics in Medicine Autoimmune DiseaseOpen-labeled Extension StudyInherited Metabolic DiseasePathogenesisPathology	2010	223
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Molecular Genetics and Metabolism Translational MedicineEnzyme Replacement TherapyPathologyMucopolysaccharidosis ViSafety Outcomes	2008	215
Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human <i>N</i>-Acetylgalactosamine 4-Sulfatase Paul Harmatz, David Ketteridge, Roberto Giugliani, PEDIATRICS	2005	213
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study Christian J. Hendriksz, Barbara K. Burton, Thomas R. Fleming, Journal of Inherited Metabolic Disease	2014	207
C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia Ravi Savarirayan, Melita Irving, Carlos A. Bacino, New England Journal of Medicine	2019	205

Page 1